Bronchogen vs Lactoferrin
A side-by-side research comparison of Bronchogen and Lactoferrin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Bronchogen | Lactoferrin |
|---|---|---|
| Full name | Bronchogen (Ala-Asp-Glu-Leu Bronchopulmonary Bioregulator) | Lactoferrin (Iron-Binding Glycoprotein) |
| Category | Immune Support | Immune Support |
| Status | Research compound (peptide bioregulator) | Dietary supplement (GRAS) |
| Mechanism | As a signal peptide (Ala-Asp-Glu-Leu), it is proposed to regulate gene expression in respiratory epithelial tissue, supporting airway lining integrity, antioxidant defense, and local respiratory immune function. | Sequesters iron from pathogens (bacteriostatic), directly disrupts bacterial membranes, activates NK cells and macrophages, and modulates inflammatory cytokines. |
| Molecular weight | ~445 Da | 80000 Da |
| Half-life | Short (peptide) | ~4-8 hours (oral absorption of fragments) |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~15-25% (oral, as bioactive fragments) |
| Typical dose | ~1-2 capsules/day or short injectable courses | 200-600 mg |
| Frequency | Once daily | 1-2x daily |
| Route | Oral capsule or subcutaneous | Oral capsule or powder |
Bronchogen reported benefits
- Respiratory/airway support
- Bronchopulmonary tissue maintenance (proposed)
- Local respiratory immune support
- Short course-based protocol
Lactoferrin reported benefits
- Broad antimicrobial activity
- Iron homeostasis regulation
- Gut immune support
- Anti-biofilm properties
- Prebiotic effects
Related comparisons
Research and educational reference only. Not medical advice.